| ·OBJECTIVE: To observe the clinical efficacy of different administration regimens of Conbercept in the treatment of polypoidal choroidal vasculopathy.·METHODS: Twenty-one patients with polypoidal choroidal vasculopathy who met the inclusion criteria and were treated in our hospital were randomly divided into two groups.The fixed administration group(9 patients and 9 eyes)was treated with 3+Q12W scheme,namely,0.5 mg conbercept ophthalmic injection was intravitreally injected every 4 weeks for 3consecutive times,and then 1 time every 12 weeks.In the prolonged administration group(12patients and 12 eyes),3+TAE scheme was carried out,that is,0.5 mg conbercept ophthalmic injection was intravitreally injected every 4 weeks for 3 consecutive times.The time of next injection was determined according to the evaluation results of each visit.The interval to the next visit/treatment was ≥ 4 weeks and ≤ 12 weeks.The best corrected visual acuity(BCVA),central retinal thickness(CRT)and the frequency of injection were compared between the two groups at 12 and 48 weeks after treatment,respectively..·RESULT: BCVA of the fixed administration group was 74.78 ± 11.23 letters and 74.67 ±13.94 letters at 12 and 48 weeks after treatment,which increased by 7.00 ± 4.21 letters and6.89 ± 4.48 letters at the baseline before treatment,respectively.The difference was statistically significant(all P<0.05).BCVA in the prolonged administration group was 77.83± 5.46 letters and 77.58 ± 8.59 letters respectively at 12 and 48 weeks after treatment,which were 8.75 ± 7.54 letters and 8.50 ± 5.60 letters higher than the baseline before treatment.The difference was statistically significant(all P<0.05).At the 12 th and 48 th week after injection,the average CRT in the group fixed administration was 276.33 ± 44.39 um and 240.56 ± 40.11 um,respectively,which were 43.22 ± 42.21 um and 79.00 ± 53.64 um lower than the baseline before treatment.The difference was statistically significant(all P<0.05).At the 12 th and 48 th week after injection,the average CRT in the prolonged administration group was 271.58 ±63.08 um and 241.00 ± 43.91 um,which were 57.42 ± 45.33 um and 88.00 ± 61.16 um lower than the baseline before treatment,respectively.The difference was statistically significant(all P<0.05).The average times of intravitreal injection of conbercept were 6.00±0.00 and7.75±1.14 times in the fixed administration group and the prolonged administration group,respectively.·CONCLUSION:Two different regimens of conbercept could reduce the CRT and improve the visual acuity of the patients with polypoidal choroidal vasculopathy.And the times of intravitreal injection in thefixed administration were less than those in the prolonged administration group.This study provides clinically meaningful research data for exploring treatment schemes that reduce the number of injections as much as possible,avoid serious adverse reactions,and save patients’ costs,and improve social and economic benefits on the basis of ensuring efficacy. |
